Статті в журналах з теми "Response to therapies"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Response to therapies".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Gayan, Chathura. "Evaluate the response of Apoptosis, Angiogenesis and Cancer Therapies." Cancer Research and Cellular Therapeutics 2, no. 1 (March 28, 2018): 01–08. http://dx.doi.org/10.31579/2640-1053/022.
Dudekula, Noor, Vikas Arora, Zsuzsanna Callaerts-Vegh, and Richard A. Bond. "The Temporal Hormesis of Drug Therapies." Dose-Response 3, no. 3 (May 1, 2005): dose—response.0. http://dx.doi.org/10.2203/dose-response.003.03.009.
Truelove, Edmond, Kimberly Hanson Huggins, Lloyd Mancl, and Samuel F. Dworkin. "NONSPLINT THERAPIES: Authors' response." Journal of the American Dental Association 137, no. 11 (November 2006): 1493–94. http://dx.doi.org/10.14219/jada.archive.2006.0070.
Prasad, Vinay, Victoria Kaestner, and Alyson Haslam. "Bridging therapies used in trials testing CAR-T therapies." Journal of Clinical Oncology 42, no. 16_suppl (June 1, 2024): e19011-e19011. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e19011.
Brown, Barbara G. "Innovative Therapies: Biological Response Modifiers." Journal of the Association of Pediatric Oncology Nurses 5, no. 1-2 (January 1988): 26. http://dx.doi.org/10.1177/104345428800500109.
Mattison, Lars, and Paul Iaizzo. "PHRENIC NERVE RESPONSE TO CRYOABLATION THERAPIES." Journal of the American College of Cardiology 65, no. 10 (March 2015): A405. http://dx.doi.org/10.1016/s0735-1097(15)60405-3.
Cunningham, Jonathan W., and Peder L. Myhre. "NT-proBNP Response to Heart Failure Therapies." Journal of the American College of Cardiology 78, no. 13 (September 2021): 1333–36. http://dx.doi.org/10.1016/j.jacc.2021.07.045.
Gerger, Armin, Melissa LaBonte, and Heinz-Josef Lenz. "Molecular Predictors of Response to Antiangiogenesis Therapies." Cancer Journal 17, no. 2 (March 2011): 134–41. http://dx.doi.org/10.1097/ppo.0b013e318212db3c.
Held, Barbara S. "Common dances, uncommon therapies: Response to Ryder." Journal of Family Psychology 1, no. 4 (1988): 476–79. http://dx.doi.org/10.1037/h0084983.
Johnston, Stephen R. D., Alexandra Leary, Lesley-Ann Martin, Ian E. Smith, and Mitch Dowsett. "Enhancing endocrine response with novel targeted therapies." Cancer 112, S3 (2008): 710–17. http://dx.doi.org/10.1002/cncr.23190.
Yanai, Henit, and Stephen B. Hanauer. "Assessing Response and Loss of Response to Biological Therapies in IBD." American Journal of Gastroenterology 106, no. 4 (April 2011): 685–98. http://dx.doi.org/10.1038/ajg.2011.103.
Chupp, Geoffrey Lowell, Ravdeep Kaur, and Anne Mainardi. "New Therapies for Emerging Endotypes of Asthma." Annual Review of Medicine 71, no. 1 (January 27, 2020): 289–302. http://dx.doi.org/10.1146/annurev-med-041818-020630.
Iacobellis, Gianluca, Alexis Elias Malavazos, Sara Basilico, Silvia Tresoldi, Rocco Francesco Rinaldo, Carola Dubini, Gloria Capitanio, et al. "Epicardial fat inflammation response to COVID‐19 therapies." Obesity 29, no. 9 (August 3, 2021): 1427–33. http://dx.doi.org/10.1002/oby.23232.
Harlé, Alexandre, and Jean-Louis Merlin. "Response predictive biomarkers to targeted therapies in oncology." Annales de biologie clinique 71, S1 (November 2013): 89–97. http://dx.doi.org/10.1684/abc.2013.0906.
Forshaw, Tom E., Reetta Holmila, Kimberly J. Nelson, Joshua E. Lewis, Melissa L. Kemp, Allen W. Tsang, Leslie B. Poole, W. Todd Lowther, and Cristina M. Furdui. "Peroxiredoxins in Cancer and Response to Radiation Therapies." Antioxidants 8, no. 1 (January 1, 2019): 11. http://dx.doi.org/10.3390/antiox8010011.
Shaked, Yuval. "The pro-tumorigenic host response to cancer therapies." Nature Reviews Cancer 19, no. 12 (October 23, 2019): 667–85. http://dx.doi.org/10.1038/s41568-019-0209-6.
Faycal, Cherine Abou, Sylvie Gazzeri, and Beatrice Eymin. "RNA splicing, cell signaling, and response to therapies." Current Opinion in Oncology 28, no. 1 (January 2016): 58–64. http://dx.doi.org/10.1097/cco.0000000000000254.
Dinarello, Charles A. "Anti-Cytokine Therapies in Response to Systemic Infection." Journal of Investigative Dermatology Symposium Proceedings 6, no. 3 (December 2001): 244–50. http://dx.doi.org/10.1046/j.0022-202x.2001.00046.x.
Stoilova, Bilyana, Rachel Moore, Marlen Metzner, Zhihong Zheng, Marina Konopleva, Courtney DiNardo, and Paresh Vyas. "Mechanisms of Response and Resistance to AML Therapies." Clinical Lymphoma Myeloma and Leukemia 20 (September 2020): S7. http://dx.doi.org/10.1016/s2152-2650(20)30442-0.
Braun, Theodore P., Christopher A. Eide, and Brian J. Druker. "Response and Resistance to BCR-ABL1-Targeted Therapies." Cancer Cell 37, no. 4 (April 2020): 530–42. http://dx.doi.org/10.1016/j.ccell.2020.03.006.
Allen, Matthew R., Janet M. Hock, and David B. Burr. "Periosteum: biology, regulation, and response to osteoporosis therapies." Bone 35, no. 5 (November 2004): 1003–12. http://dx.doi.org/10.1016/j.bone.2004.07.014.
Bergeron, Michel G. "Biological Response Modifiers - The Therapies of the Future." Canadian Journal of Infectious Diseases 3, suppl b (1992): 1–2. http://dx.doi.org/10.1155/1992/461649.
RIVERA, TANIA L., H. MICHAEL BELMONT, SEEMA MALANI, MELISSA LATORRE, LAURI BENTON, JOSEPH WEISSTUCH, LAURA BARISONI, et al. "Current Therapies for Lupus Nephritis in an Ethnically Heterogeneous Cohort." Journal of Rheumatology 36, no. 2 (February 2009): 298–305. http://dx.doi.org/10.3899/jrheum.080335.
Setlai, Botle Precious, Rodney Hull, Meshack Bida, Chrisna Durandt, Thanyani Victor Mulaudzi, Aristotelis Chatziioannou, and Zodwa Dlamini. "Immunosuppressive Signaling Pathways as Targeted Cancer Therapies." Biomedicines 10, no. 3 (March 16, 2022): 682. http://dx.doi.org/10.3390/biomedicines10030682.
Siegel, Jay P. "Clinical Development of Biological Response Modifiers." Canadian Journal of Infectious Diseases 5, suppl a (1994): 5A—8A. http://dx.doi.org/10.1155/1994/583805.
Asif, Samia, and Benjamin A. Teply. "Biomarkers for Treatment Response in Advanced Prostate Cancer." Cancers 13, no. 22 (November 16, 2021): 5723. http://dx.doi.org/10.3390/cancers13225723.
Smolock, Amanda R., and Sarah B. White. "Immune Response to Locoregional Therapy." Digestive Disease Interventions 06, no. 01 (January 4, 2022): 037–40. http://dx.doi.org/10.1055/s-0041-1742102.
Audia, Sylvain, and Bernard Bonnotte. "Emerging Therapies in Immune Thrombocytopenia." Journal of Clinical Medicine 10, no. 5 (March 2, 2021): 1004. http://dx.doi.org/10.3390/jcm10051004.
Garcillán, Beatriz, Miguel Salavert, José R. Regueiro, and Sabela Díaz-Castroverde. "Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review." Vaccines 10, no. 2 (February 15, 2022): 297. http://dx.doi.org/10.3390/vaccines10020297.
Kolarich, Andrew R., Iakovos Theodoulou, and Christos Georgiades. "Combination Therapies with Ablation: Immunoablation." Digestive Disease Interventions 04, no. 04 (November 19, 2020): 358–64. http://dx.doi.org/10.1055/s-0040-1721453.
Bhatia, Ankush, Vaios Hatzoglou, Gary Ulaner, Raajit Rampal, David M. Hyman, Omar Abdel-Wahab, Benjamin H. Durham, et al. "Neurologic and oncologic features of Erdheim–Chester disease: a 30-patient series." Neuro-Oncology 22, no. 7 (January 17, 2020): 979–92. http://dx.doi.org/10.1093/neuonc/noaa008.
de Mestier, Louis, Clarisse Dromain, Gaspard d'Assignies, Jean-Yves Scoazec, Nathalie Lassau, Rachida Lebtahi, Hedia Brixi, et al. "Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art." Endocrine-Related Cancer 21, no. 3 (December 18, 2013): R105—R120. http://dx.doi.org/10.1530/erc-13-0365.
Zawistowski, Jon S., Lee M. Graves, and Gary L. Johnson. "Assessing adaptation of the cancer kinome in response to targeted therapies." Biochemical Society Transactions 42, no. 4 (August 1, 2014): 765–69. http://dx.doi.org/10.1042/bst20130274.
Lutfi, Nura, Miguel Alejandro Galindo-Campos, and José Yélamos. "Impact of DNA Damage Response—Targeted Therapies on the Immune Response to Tumours." Cancers 13, no. 23 (November 29, 2021): 6008. http://dx.doi.org/10.3390/cancers13236008.
Klineova, Sylvia, Rebecca Straus Farber, Tracy DeAngelis, Tungming Leung, Tyler Smith, Richard Blanck, Lana Zhovtis-Ryerson, and Asaff Harel. "Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2)." Multiple Sclerosis Journal 29, no. 8 (July 2023): 990–1000. http://dx.doi.org/10.1177/13524585231185246.
Stewart, A. Keith. "Novel therapies for relapsed myeloma." Hematology 2009, no. 1 (January 1, 2009): 578–86. http://dx.doi.org/10.1182/asheducation-2009.1.578.
Blair, Edward D., Martina Kaufmann, and Mieke Keppens. "Prediction of response to targeted and immune checkpoint therapies." Personalized Medicine 15, no. 1 (January 2018): 45–56. http://dx.doi.org/10.2217/pme-2017-0051.
Ghali, Jalal K., and JoAnn Lindenfeld. "Sex differences in response to chronic heart failure therapies." Expert Review of Cardiovascular Therapy 6, no. 4 (April 2008): 555–65. http://dx.doi.org/10.1586/14779072.6.4.555.
Vaquero, Javier, Allan Pavy, Ester Gonzalez-Sanchez, Mark Meredith, Ander Arbelaiz, and Laura Fouassier. "Genetic alterations shaping tumor response to anti-EGFR therapies." Drug Resistance Updates 64 (September 2022): 100863. http://dx.doi.org/10.1016/j.drup.2022.100863.
Lim, Kok Haw Jonathan, Evangelos Giampazolias, Oliver Schulz, Neil C. Rogers, Anna Wilkins, Erik Sahai, Jessica Strid, and Caetano Reis e Sousa. "Loss of secreted gelsolin enhances response to anticancer therapies." Journal for ImmunoTherapy of Cancer 10, no. 9 (September 2022): e005245. http://dx.doi.org/10.1136/jitc-2022-005245.
Galons, Jean Philippe, David L. Morse, Dominique R. Jennings, and Robert J. Gillies. "Diffusion-Weighted MRI and Response to Anti-Cancer Therapies." Israel Journal of Chemistry 43, no. 1-2 (November 2003): 91–101. http://dx.doi.org/10.1560/gj5m-pp8r-ghub-vuup.
Chan, Happy, and Prabha Ranganathan. "Will Pharmacogenetics Predict Response to Therapies in Rheumatoid Arthritis?" Current Pharmacogenomics 4, no. 4 (December 1, 2006): 307–19. http://dx.doi.org/10.2174/157016006778992750.
Leader, Darian. "RESPONSE TO ‘THE FUTURE OF THE TRANSFERENCE-BASED THERAPIES’." British Journal of Psychotherapy 25, no. 3 (August 2009): 349–51. http://dx.doi.org/10.1111/j.1752-0118.2009.01128.x.
Lepper, Georgia. "RESPONSE TO ‘THE FUTURE OF THE TRANSFERENCE-BASED THERAPIES’." British Journal of Psychotherapy 25, no. 3 (August 2009): 352–56. http://dx.doi.org/10.1111/j.1752-0118.2009.01129.x.
Stroehl, Yasmin W., Brian S. Letzen, Johanna M. M. van Breugel, Jean-Francois Geschwind, and Julius Chapiro. "Intra-arterial therapies for liver cancer: assessing tumor response." Expert Review of Anticancer Therapy 17, no. 2 (December 27, 2016): 119–27. http://dx.doi.org/10.1080/14737140.2017.1273775.
Smith, Kevin R. "Anomalous Therapies and Public Health: A Utilitarian Bioethical Response." Public Health Nursing 25, no. 3 (May 2008): 269–77. http://dx.doi.org/10.1111/j.1525-1446.2008.00704.x.
Reider, Bruce. "PRP Therapies—Is It Time for Potency Assays? Response." American Journal of Sports Medicine 44, no. 11 (October 31, 2016): NP64. http://dx.doi.org/10.1177/0363546516676456.
Amoaku, W. M., U. Chakravarthy, R. Gale, M. Gavin, F. Ghanchi, J. Gibson, S. Harding, et al. "Defining response to anti-VEGF therapies in neovascular AMD." Eye 29, no. 6 (April 17, 2015): 721–31. http://dx.doi.org/10.1038/eye.2015.48.
Teicher, Beverly A. "Role of angiogenesis in the response to anticancer therapies." Drug Resistance Updates 1, no. 1 (March 1998): 59–61. http://dx.doi.org/10.1016/s1368-7646(98)80215-x.
Bignami, M., I. Casorelli, and P. Karran. "Mismatch repair and response to DNA-damaging antitumour therapies." European Journal of Cancer 39, no. 15 (October 2003): 2142–49. http://dx.doi.org/10.1016/s0959-8049(03)00569-0.